Regenerative medicine company Orthocell Limited (ASX:OCC) has been granted a patent in China for its Celgro collagen technology. Shares in the company pushed more than 2 per cent higher yesterday on the news.
The company says the patent covers the manufacture of biological materials to repair damaged soft tissue.
Managing Director Paul Anderson says this further strengthens the company’s global intellectual property position for its unique regeneratice therapies.
He says this comes at a time when the company is moving its products through international registration processes.
Orthocell reported a net loss of $2.18 million in the 2014 financial year.
